Head-to-head · Cost-Efficiency Index
boostAGErx vs Ivy Rx
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
boostAGErx
Cost-sensitive shoppers prepaying 12 months for low-cost GLP-1.
Visit boostAGErxIvy Rx
Cost-first shoppers who want the lowest published entry price on a semaglutide microdose, for shoppers comfortable with unresolved pricing terms.
Visit Ivy RxThe verdict
boostAGErx and Ivy Rx tie on the Cost-Efficiency Index at 69/100, so neither wins outright on the numbers. For most shoppers we'd start with boostAGErx (ranked #96, a hair above #102) — Cost-sensitive shoppers prepaying 12 months for low-cost GLP-1. But Ivy Rx is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs boostAGErx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | boostAGErx | Ivy Rx |
|---|---|---|
| Cost-Efficiency Index | 69/100 | 69/100 |
| Semaglutide / mo | $95/mo (billed every 28 days, compounded) | $97/mo (microdose tier, promotional rate, compounded) |
| Tirzepatide / mo | $145/mo (billed every 28 days, compounded) | $199/mo (brand Mounjaro, compounded) |
| Semaglutide / yr (modeled) | $1,140 | $1,164 |
| Tirzepatide / yr (modeled) | $1,740 | $2,388 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #96 | #102 |
boostAGErx
69/100Where the value is
- Compounded GLP-1 starting around $95/mo (12-month plan paid upfront)
- Free shipping and clinical evaluation included
- Membership fee refunded in full if you're not approved
The tradeoffs
- Billing runs on a 28-day cycle rather than a calendar month — thirteen charges a year, so the $145 tirzepatide rate is $1,885 a year, an effective $157/mo
- The terms call the charge a 'membership fee' while the marketing carousel says 'No Membership Fees Ever'
Ivy Rx
69/100Where the value is
- Genuinely low entry price on the semaglutide microdose tier ($77/mo)
- HSA/FSA eligible with itemized receipts for reimbursement
- Legal entity is named (Ivy RX PLLC), which many competitors in this batch do not disclose
The tradeoffs
- The standard semaglutide price is shown as a struck-through discount ('$197 $97') with no label clarifying whether $97 is a standing rate or a temporary promo
- The advertised $199/mo tirzepatide rate requires a 12-month upfront lump-sum payment, not month-to-month billing, and a separate unexplained $1,399 vial price appears on the same page
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.